These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 11248834)
21. The prevalence of the ocular side effects of chlorpromazine in the Tuscaloosa Veterans Administration patient population. Alexander LJ; Bowerman L; Thompson LR J Am Optom Assoc; 1985 Nov; 56(11):872-6. PubMed ID: 4078212 [TBL] [Abstract][Full Text] [Related]
28. [Complications on the part of the eyes during employment of psychotropic drugs (review of the foreign literature)]. Gol'dovskaia IL Zh Nevropatol Psikhiatr Im S S Korsakova; 1969; 69(6):935-9. PubMed ID: 4905472 [No Abstract] [Full Text] [Related]
29. Neuroleptic-induced skin pigmentation in chronic hospitalized schizophrenic patients. Ban TA; Guy W; Wilson WH Can J Psychiatry; 1985 Oct; 30(6):406-8. PubMed ID: 2866025 [TBL] [Abstract][Full Text] [Related]
30. In vivo observations of chlorpromazine ocular deposits in a patient on long-term chlorpromazine therapy. Razeghinejad MR; Nowroozzadeh MH; Zamani M; Amini N Clin Exp Ophthalmol; 2008 Aug; 36(6):560-3. PubMed ID: 18954320 [TBL] [Abstract][Full Text] [Related]
31. [Persistence of bilateral pigmentary deposits in stromal cornea in a woman after a brief treatment with antidepressants]. Panzitt M; Simon M; Weger M Klin Monbl Augenheilkd; 2001 Apr; 218(4):273-5. PubMed ID: 11392274 [TBL] [Abstract][Full Text] [Related]
32. Re: Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes. O'Croinin F; Zibin T J Psychiatry Neurosci; 1994 May; 19(3):226. PubMed ID: 8031748 [No Abstract] [Full Text] [Related]
33. Drug-induced corneal deposits: an up-to-date review. Sahyoun JY; Sabeti S; Robert MC BMJ Open Ophthalmol; 2022; 7(1):e000943. PubMed ID: 35415268 [TBL] [Abstract][Full Text] [Related]
34. A Case Report: Anti-Psychotic Agents Related Ocular Toxicity. Choy BNK; Ng ALK; Shum JWH; Fan MCY; Lai JSM Medicine (Baltimore); 2016 Apr; 95(15):e3360. PubMed ID: 27082594 [TBL] [Abstract][Full Text] [Related]
35. Cutaneous and ocular changes associated with the use of chlorpromazine. Wolf ME; Richer S; Berk MA; Mosnaim AD Int J Clin Pharmacol Ther Toxicol; 1993 Aug; 31(8):365-7. PubMed ID: 8225679 [TBL] [Abstract][Full Text] [Related]
36. Chlorpromazine corneal toxicity. Johnson AW; Buffaloe WJ South Med J; 1968 Sep; 61(9):993-4. PubMed ID: 5676587 [No Abstract] [Full Text] [Related]
37. Long term evolution of the side-effect lens opacities induced by chlorpromazine prolonged therapy. Baron JB; Rivoalan Y; Morel P Agressologie; 1971; 12(1):57-60. PubMed ID: 5088348 [No Abstract] [Full Text] [Related]
38. DERMATOLOGICAL AND OPHTHALMOLOGICAL CHANGES ASSOCIATED WITH PROLONGED CHLORPROMAZINE THERAPY. FELDMAN PE; FRIERSON BD Am J Psychiatry; 1964 Aug; 121():187-8. PubMed ID: 14194222 [No Abstract] [Full Text] [Related]
39. Toxic effects of phenothiazines on the eye. Boet DJ Doc Ophthalmol; 1970 Jul; 28(1):1-69. PubMed ID: 5312274 [No Abstract] [Full Text] [Related]
40. Loxapine as an alternative to phenothiazines in a case of oculocutaneous skin pigmentation. Ewing DG; Einarson TR Am J Psychiatry; 1981 Dec; 138(12):1631-2. PubMed ID: 7304801 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]